Traws Pharma Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
TRAW$0.23-6.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| · · Nine Months Ended September 30, · | |||||||
| · 2024 · 2023 | |||||||
| Operating activities: | | | | | | | |
| Net loss | | $(136,601,000) | | $(14,764,000) | | ||
| Adjustment to reconcile net loss to net cash used in operating activities: | | | | | | | |
| Acquired in-process research and development | | | 117,464,000 | | | — | |
| Depreciation and amortization | | 10,000 | | 12,000 | | ||
| Stock compensation | | 1,056,000 | | 969,000 | | ||
| Changes in assets and liabilities: | | | | | | | |
| Receivables | | (2,103,000) | | 11,000 | | ||
| Prepaid expenses and other current assets | | 429,000 | | (1,188,000) | | ||
| Other assets | | | — | | | — | |
| Accounts payable | | (147,000) | | 2,288,000 | | ||
| Accrued expenses and other current liabilities | | (5,690,000) | | (660,000) | | ||
| Deferred revenue | | (170,000) | | (170,000) | | ||
| Net cash used in operating activities | | (25,752,000) | | (13,502,000) | | ||
| | | | | | | | |
| Investing activities: | | | | | | | |
| Cash paid for acquisition. net of cash acquired | | | (3,648,000) | | | — | |
| Payments for purchase of property and equipment | | | — | | | (14,000) | |
| Net cash used in investing activities | | (3,648,000) | | (14,000) | | ||
| | | | | | | | |
| Financing activities: | | | | | | | |
| Proceeds from sale of common and preferred stock in connection with the private placement, net of expenses | | | 13,999,000 | | | — | |
| Net cash provided by financing activities | | 13,999,000 | | — | | ||
| Effect of foreign currency translation on cash | | (10,000) | | 3,000 | | ||
| Net decrease in cash and cash equivalents | | (15,411,000) | | (13,513,000) | | ||
| Cash and cash equivalents at beginning of period | | 20,821,000 | | 38,757,000 | | ||
| Cash and cash equivalents at end of period | | $5,410,000 | | $25,244,000 | | ||
| Supplemental disclosure of cash flow information: | | | | | | | |
| Preferred stock issued in connection with the reclassification and conversion of redeemable convertible preferred stock | | $111,619,000 | | $— | | ||
| Common stock issued in connection with acquisition of Trawsfynydd | | $3,719,000 | | $— | | ||
| Preferred stock issued in connection with acquisition of Trawsfynydd | | $98,047,000 | | $— | | ||
Notes to Condensed Consolidated Financial Statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.